Skip to main content

Table 2 Neovascular age related macular degeneration therapies in the pipeline

From: Pipeline therapies for neovascular age related macular degeneration

Class Brand name, manufacturer Target/mechanism Status
Biosimilars Razumab (Intas Pharmaceuticals Ltd., Ahmedabad, India) Ranibizumab biosimilar Approved
FYB 201 (Formycon AG, Munich, Germany and Bioeq Gmbh Holzkirchen, Germany) Ranibizumab biosimilar Phase III trial completed
SB-11 (Samsung Bioepsis, Incheon, South Korea) Ranibizumab biosimilar Phase III trial completed
Xlucane (Xbrane Biopharma, Solna, Sweden) Ranibizumab biosimilar Phase III trial underway
PF582 (Pfnex, San Diego, California) Ranibizumab biosimilar Phase I/II trial completed
CHS3551 (Coherus BioSciences, Redwood City, California) Ranibizumab biosimilar Pre-clinical investigation
FYB203 (Formycon AG, Munich, Germany and Bioeq Gmbh Holzkirchen, Germany) Aflibercept biosimilar Pre-clinical investigation
ALT-L9 (Alteogen, Deajeon, South Korea) Aflibercept biosimilar Entering phase I trial
MYL1710 (Momenta Pharamaceuticals, Cambridge, MA, and Mylan Pharmacueticals, Canonsburg, PA) Aflibercept biosimilar Phase III trial underway
CHS-2020 (Coherus BioSciences, Redwood City, California) Aflibercept biosimilar Pre-clinical investigation
ONS-5010 (Lytenava, Outlook Therapeutics, Cranberry Township, New Jersey) Bevacizumab biosimilar Phase III trial completed
Anti-VEGF Abicipar pegol (Abicipar; Allergan, Coolock, Dublin) VEGF-A Phase III trial completed
OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne) VEGF-C and VEGF-D Phase IIb trial completed
Conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan) VEGF-A, VEGF-B, and PGF Phase III trial underway
KSI-301 (Kodiak Sciences, Palo Alto, CA) VEGF-A Phase II trial underway
Anti- PDGF CLS-AX (Ataxinib; Clearside Biomedical, Alpharetta, Georgia) VEGF and PDGF Pre-clinical investigation
DE-120 (Santen Pharmaceuticals, Kita-Ku, Osaka) VEGF-A and PDGF Pre-clinical investigation halted
Pegpleranib (Fovista; Ophthotech, Princeton, New Jersey) PDGF-BB and PDGF-AB Phase III trial completed
Rinucumab (Regeneron, Tarrytown, New York) PDGF-B Phase II trial completed
X-82 (Tyrogenex, Rockville, Maryland) VEGF-A and PDGF Phase II trial completed
Anti-tissue factor (TF) ICON-1 (Iconic Therapeutics, San Francisco, California) TF and natural killer cells Phase II trial completed
Tie-2 receptor Faricimab (Roche/Genentech, San Francisco, CA) VEGF-A and Ang-2 Phase II trial completed
REGN910 (Nevascumab; Regeneron, Tarrytown, New York) Ang-2 Phase II trial completed
ARP-1536 (Aerpio Therapeutics, Blue Ash, Ohio) VE-PTP Pre-clinical investigation
DE-122 (Carotuximab; Santen, Kita-Ku, Osaka, and TRACON Pharmaceuticals, San Diego, CA) Endoglin Phase II trial completed
AXT-107 (AsclepiX Therapeutics, Jersey City, New Jersey), inhibits both VEGFR2 Pre-clinical investigation
Sustained treatments Ranibizumab PDS (Genentech, San Francisco, CA) VEGF-A Phase III completed
GB-102 (Sunitinib maleate; GrayBug Vision, Redwood City, CA) VEGF-A and PDGF Phase II underway
OTX-TKI, a hydrogel depot of the tyrosine kinase inhibitor, sunitinib (Ocular Therapeutix; Bedford, Massachusetts) VEGF and PDGF Phase I underway
Durasert Bioerodible TKI (Durasert; EyePoint Pharmaceuticals, Watertown, Massachusetts) VEGF and PDGF Pre-clinical investigation
ENV1305 (Envisia Therapeutics, Morrisville, North Carolina) VEGF-A Pre-clinical investigation
NT-503 (Neurotech, Cumberland, Rhode Island) VEGF-A Pre-clinical investigation
Gene therapy Adeno-associated virus type 2 (AAV2)-sFlt-1 (Genzyme, Cambridge, Massachusetts) Produces sFlt-1, a soluble isoform of VEGFR-1, and an antagonist of VEGF Phase I trial completed
rAAV.SFLT-1 (AVA-101; Avalanche Biotechnologies, Redwood City, California) Produces sFlt-1, a soluble isoform of VEGFR-1, and an antagonist of VEGF Phase II trial completed
ADVM-022 and ADVM-032 (Adverum Biotechnologies, Redwood City, California) Produces aflibercept-like protein and ranibizumab-like protein Phase I trial completed
RGX-314 (REGENXBIO, Rockville, Maryland) Vector expressing a protein similar to ranibizumab Phase I/II underway
Retinostat (Oxford Biomedica, Cowley, Oxford) Codes for endostatin and angiostatin Phase I completed
AAVCAGsCD59 (HMR59; Hemera Biosciences, Waltham, Massachusetts) Produces CD59 Phase I underway
Oral treatments AKST4290 (Alkahest, San Carlos, California) Targets CCR3 Phase II completed
Topical treatments PAN-90806 (PanOptica, Mount Arlington, New Jersey) VEGF-A and PDGF Phase II completed
Pazopanib (GlaxoSmithKline, Brentford, London) VEGF-A and PDGF Phase II completed
OHR-102 (Squalamine lactate, Ohr Pharmaceutical, New York, New York) VEGF, PDGF, and b-FGF Phase II completed
Regorafenib (Stivarga, Bayer Healthcare, Leverkusen, North-Rhine, Westphalia) VEGF-A and PDGF Phase II completed
LHA510 (Alcon, Geneva, Switzerland) Tyrosine kinase Phase II completed